Inflammasome, inflammation and cancer: An interrelated pathobiological triad

Current Drug Targets

Volumn 16, Issue 3, 2015, Pages 249-257

  Müzesmuzes, Györgyi ^a   Sipos, Ferenc ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Cancer; Caspase 1; Inflammasome; Inflammation; Pro inflammatory cytokines; Pyroptosis

Indexed keywords

CASPASE 11; CASPASE 8; CRYOPYRIN; EPITHELIAL CELL ADHESION MOLECULE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLAMMASOME; INTERLEUKIN 1; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 18 RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 33; INTERLEUKIN 6; MYELOID DIFFERENTIATION FACTOR 88; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR 12; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR 3; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR 4; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR 6; PROTEIN BCL 2; PROTEIN BCL XL; STAT3 PROTEIN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER RISK; CARCINOGENESIS; COLORECTAL CANCER; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; ENZYME ACTIVATION; EPITHELIAL MESENCHYMAL TRANSITION; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INNATE IMMUNITY; NEOPLASM; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DELIVERY SYSTEM; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; NEOPLASMS; TRENDS;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOGENESIS; DRUG DELIVERY SYSTEMS; HUMANS; INFLAMMASOMES; INFLAMMATION; NEOPLASMS;

EID: 84930979471     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450115666141229154157     Document Type: Article

References (141)

1. [1] Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancerrelated inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009; 30: 1073-81.
2. [2] Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
3. [3] Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005; 7: 211-7.
4. [4] Mantovani A. Cancer: inflammation by remote control. Nature 2005; 435: 752-3.
5. [5] Kuper H, Adami HO, Trichopoulos D. Infections as a major preventable cause of human cancer. J Intern Med 2000; 248: 171-83.
6. [6] Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
7. [7] Elinav E, Nowarski R, Thaiss CA, et al. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer 2013; 13: 759-71.
8. [8] Kamada N, Seo SU, Chen GY, Núñez G. Role of the gut microbiota in immunity and inflammatory disease. Nat Rev Immunol 2013; 13: 321-35.
9. [9] Rider P, Carmi Y, Guttman O, et al. IL-1α and IL-1β recruit different myeloid cells and promote different stages of sterile inflammation. J Immunol 2011; 187: 4835-43.
10. [10] Shaw AC, Goldstein DR, Montgomery RR. Age-dependent dysregulation of innate immunity. Nat Rev Immunol 2013; 13: 875-87.
11. [11] Franceschi C, Bonafè M, Valensin S, et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann NY Acad Sci 2000; 908: 244-54.
12. [12] Finkel T, Serrano M, Blasco MA. The common biology of cancer and ageing. Nature 2007; 448: 767-74.
13. [13] Campisi J. Aging, cellular senescence, and cancer. Annu Rev Physiol 2013; 75: 685-705.
14. [14] Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011; 34: 637-50.
15. [15] Kato H, Takahasi K, Fujita T. RIG-I-like receptors: cytoplasmic sensors for non-self RNA. Immunol Rev 2011; 243: 91-8.
16. [16] Creagh EM, O'Neill LA. TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity. Trends Immunol 2006; 27: 352-7.
17. [17] Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010; 140: 805-20.
18. [18] Schroder K, Tschopp J. The inflammasomes. Cell 2010; 140: 821-32.
19. [19] Takeda K, Takeuchi O, Akira S. Recognition of lipopeptides by Toll-like receptors. J Endotoxin Res 2002; 8: 459-63.
20. [20] Gross O, Thomas CJ, Guarda G, Tschopp J. The inflammasome: an integrated view. Immunol Rev 2011; 243: 136-51.
21. [21] Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002; 10: 417-26.
22. [22] Lamkanfi M, Dixit VM. Inflammasomes and their roles in health and disease. Annu Rev Cell Dev Biol 2012; 28: 137-61.
23. [23] Strowig T, Henao-Mejia J, Elinav E, Flavell R. Inflammasomes in health and disease. Nature 2012; 481: 278-86.
24. [24] Janowski AM, Kolb R, Zhang W, Sutterwala FS. Beneficial and Detrimental Roles of NLRs in Carcinogenesis. Front Immunol 2013; 4: 370.
25. [25] Drexler SK, Yazdi AS. Complex roles of inflammasomes in carcinogenesis. Cancer J 2013; 19: 468-72.
26. [26] Kolb R, Liu GH, Janowski AM, Sutterwala FS, Zhang W. Inflammasomes in cancer: a double-edged sword. Protein Cell 2014; 5: 12-20.
27. [27] Ye Z, Ting JP. NLR, the nucleotide-binding domain leucine-rich repeat containing gene family. Curr Opin Immunol 2008; 20: 3-9.
28. [28] Mariathasan S, Monack DM. Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation. Nat Rev Immunol 2007; 7: 31-40.
29. [29] Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol 2009; 27: 229-65.
30. [30] Inohara N, Nuñez G. NODs: intracellular proteins involved in inflammation and apoptosis. Nat Rev Immunol 2003; 3: 371-82.
31. [31] Martinon F, Tschopp J. NLRs join TLRs as innate sensors of pathogens. Trends Immunol 2005; 26: 447-54.
32. [32] Bella J, Hindle KL, McEwan PA, Lovell SC. The leucine-rich repeat structure. Cell Mol Life Sci 2008; 65: 2307-33.
33. [33] Bauernfeind F, Ablasser A, Bartok E, et al. Inflammasomes: current understanding and open questions. Cell Mol Life Sci 2011; 68: 765-83.
34. [34] Ting JP, Lovering RC, Alnemri ES, et al. The NLR gene family: a standard nomenclature. Immunity 2008; 28: 285-7.
35. [35] Bauernfeind F, Hornung V. Of inflammasomes and pathogens--sensing of microbes by the inflammasome. EMBO Mol Med 2013; 5: 814-26.
36. [36] Lamkanfi M, Kanneganti TD, Franchi L, Núñez G. Caspase-1 inflammasomes in infection and inflammation. J Leukoc Biol 2007; 82: 220-5.
37. [37] Stutz A, Horvath GL, Monks BG, Latz E. ASC speck formation as a readout for inflammasome activation. Methods Mol Biol 2013; 1040: 91-101.
38. [38] Di Virgilio F. The therapeutic potential of modifying inflammasomes and NOD-like receptors. Pharmacol Rev 2013; 65: 872-905.
39. [39] Wen H, Miao EA, Ting JP. Mechanisms of NOD-like receptorassociated inflammasome activation. Immunity 2013; 39: 432-41.
40. [40] Mayor A, Martinon F, De Smedt T, Pétrilli V, Tschopp J. A crucial function of SGT1 and HSP90 in inflammasome activity links mammalian and plant innate immune responses. Nat Immunol 2007; 8: 497-503.
41. [41] Davis BK, Wen H, Ting JP. The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu Rev Immunol 2011; 29: 707-35.
42. [42] Bergsbaken T, Fink SL, Cookson BT. Pyroptosis: host cell death and inflammation. Nat Rev Microbiol 2009; 7: 99-109.
43. [43] Kepp O, Galluzzi L, Zitvogel L, Kroemer G. Pyroptosis-a cell death modality of its kind? Eur J Immunol 2010; 40: 627-30.
44. [44] Miao EA, Rajan JV, Aderem A. Caspase-1-induced pyroptotic cell death. Immunol Rev 2011; 243: 206-14.
45. [45] Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009; 27: 519-50.
46. [46] Smith DE. The biological paths of IL-1 family members IL-18 and IL-33. J Leukoc Biol 2011; 89: 383-92.
47. [47] Fernandes-Alnemri T, Wu J, Yu JW, et al. The pyroptosome: a supramolecular assembly of ASC dimers mediating inflammatory cell death via caspase-1 activation. Cell Death Differ 2007; 14: 1590-604.
48. [48] Rathinam VA, Vanaja SK, Fitzgerald KA. Regulation of inflammasome signaling. Nat Immunol 2012; 13: 333-42.
49. [49] Franchi L, Eigenbrod T, Muñoz-Planillo R, Nuñez G. The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol 2009; 10: 241-7.
50. [50] Kayagaki N, Warming S, Lamkanfi M, et al. Non-canonical inflammasome activation targets caspase-11. Nature 2011; 479: 117-21.
51. [51] Dupaul-Chicoine J, Saleh M. A new path to IL-1β production controlled by caspase-8. Nat Immunol 2012; 13: 211-2.
52. [52] Lamkanfi M. Emerging inflammasome effector mechanisms. Nat Rev Immunol 2011; 11: 213-20.
53. [53] Bossaller L, Chiang PI, Schmidt-Lauber C, et al. Cutting edge: FAS (CD95) mediates noncanonical IL-1β and IL-18 maturation via caspase-8 in an RIP3-independent manner. J Immunol 2012; 189: 5508-12.
54. [54] Kang TB, Yang SH, Toth B, Kovalenko A, Wallach D. Caspase-8 blocks kinase RIPK3-mediated activation of the NLRP3 inflammasome. Immunity 2013; 38: 27-40.
55. [55] Sagulenko V, Thygesen SJ, Sester DP, et al. AIM2 and NLRP3 inflammasomes activate both apoptotic and pyroptotic death pathways via ASC. Cell Death Differ 2013; 20: 1149-60.
56. [56] Shimada K, Crother TR, Karlin J, et al. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity 2012; 36: 401-14.
57. [57] Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes. Nat Rev Immunol 2013; 13: 397-411.
58. [58] Verma D, Bivik C, Farahani E, et al. Inflammasome polymorphisms confer susceptibility to sporadic malignant melanoma. Pigment Cell Melanoma Res 2012; 25: 506-13.
59. [59] Ungerbäck J, Belenki D, Jawad ul-Hassan A, et al. Genetic variation and alterations of genes involved in NFκB/TNFAIP3-and NLRP3-inflammasome signaling affect susceptibility and outcome of colorectal cancer. Carcinogenesis 2012; 33: 2126-34.
60. [60] Voronov E, Dotan S, Krelin Y, et al. Unique Versus Redundant Functions of IL-1α and IL-1β in the Tumor Microenvironment. Front Immunol 2013; 4: 177.
61. [61] Okamoto M, Liu W, Luo Y, et al. Constitutively active inflammasome in human melanoma cells mediating autoinflammation via caspase-1 processing and secretion of interleukin-1beta. J Biol Chem 2010; 285: 6477-88.
62. [62] Negash AA, Ramos HJ, Crochet N, et al. IL-1β production through the NLRP3 inflammasome by hepatic macrophages links hepatitis C virus infection with liver inflammation and disease. PLoS Pathog 2013; 9: e1003330.
63. [63] Chow MT, Sceneay J, Paget C, et al. NLRP3 suppresses NK cellmediated responses to carcinogen-induced tumors and metastases. Cancer Res 2012; 72: 5721-32.
64. [64] Bauer C, Duewell P, Mayer C, et al. Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. Gut 2010; 59: 1192-9.
65. [65] van Deventer HW, Burgents JE, Wu QP, et al. The inflammasome component NLRP3 impairs antitumor vaccine by enhancing the accumulation of tumor-associated myeloid-derived suppressor cells. Cancer Res 2010; 70: 10161-9.
66. [66] Hirota SA, Ng J, Lueng A, et al. NLRP3 inflammasome plays a key role in the regulation of intestinal homeostasis. Inflamm Bowel Dis 2011; 17: 1359-72.
67. [67] Zaki MH, Boyd KL, Vogel P, et al. The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity 2010; 32: 379-91.
68. [68] Allen IC, TeKippe EM, Woodford RM, et al. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J Exp Med 2010; 207: 1045-56.
69. [69] Villani AC, Lemire M, Fortin G, et al. Common variants in the NLRP3 region contribute to Crohn's disease susceptibility. Nat Genet 2009; 41: 71-6.
70. [70] Zaki MH, Vogel P, Body-Malapel M, Lamkanfi M, Kanneganti TD. IL-18 production downstream of the Nlrp3 inflammasome confers protection against colorectal tumor formation. J Immunol 2010; 185: 4912-20.
71. [71] Dupaul-Chicoine J, Yeretssian G, Doiron K, et al. Control of intestinal homeostasis, colitis, and colitis-associated colorectal cancer by the inflammatory caspases. Immunity 2010; 32: 367-78.
72. [72] Hu B, Elinav E, Huber S, et al. Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4. Proc Natl Acad Sci USA 2010; 107: 21635-40.
73. [73] Sadasivam S, Gupta S, Radha V, et al. Caspase-1 activator Ipaf is a p53-inducible gene involved in apoptosis. Oncogene 2005; 24: 627-36.
74. [74] Hu B, Elinav E, Flavell RA. Inflammasome-mediated suppression of inflammation-induced colorectal cancer progression is mediated by direct regulation of epithelial cell proliferation. Cell Cycle 2011; 10: 1936-9.
75. [75] Garaude J, Kent A, van Rooijen N, Blander JM. Simultaneous targeting of toll-and nod-like receptors induces effective tumorspecific immune responses. Sci Transl Med 2012; 4: 120-16.
76. [76] Elinav E, Strowig T, Kau AL, et al. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 2011; 145: 745-57.
77. [77] Chen GY, Liu M, Wang F, Bertin J, Núñez G. A functional role for Nlrp6 in intestinal inflammation and tumorigenesis. J Immunol 2011; 186: 7187-94.
78. [78] Normand S, Delanoye-Crespin A, Bressenot A, et al. Nod-like receptor pyrin domain-containing protein 6 (NLRP6) controls epithelial self-renewal and colorectal carcinogenesis upon injury. Proc Natl Acad Sci USA 2011; 108: 9601-6.
79. [79] Zaki MH, Vogel P, Malireddi RK, et al. The NOD-like receptor NLRP12 attenuates colon inflammation and tumorigenesis. Cancer Cell 2011; 20: 649-60.
80. [80] Allen IC, Wilson JE, Schneider M, et al. NLRP12 suppresses colon inflammation and tumorigenesis through the negative regulation of noncanonical NF-κB signaling. Immunity 2012; 36: 742-54.
81. [81] Chen GY. Role of Nlrp6 and Nlrp12 in the maintenance of intestinal homeostasis. Eur J Immunol 2014; 44: 321-7.
82. [82] Medzhitov R, Preston-Hurlburt P, Kopp E, et al. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol Cell 1998; 2: 253-8.
83. [83] Takeda K, Akira S. TLR signaling pathways. Semin Immunol 2004; 16: 3-9.
84. [84] O'Neill LA. How Toll-like receptors signal: what we know and what we don't know. Curr Opin Immunol 2006; 18: 3-9.
85. [85] Huang B, Zhao J, Li H, et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 2005; 65: 5009-14.
86. [86] Basith S, Manavalan B, Yoo TH, Kim SG, Choi S. Roles of tolllike receptors in cancer: a double-edged sword for defense and offense. Arch Pharm Res 2012; 35: 1297-316.
87. [87] Pikarsky E, Porat RM, Stein I, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004; 431: 461-6.
88. [88] Corcoran RB, Contino G, Deshpande V, et al. STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Res 2011; 71: 5020-9.
89. [89] Ernst M, Putoczki TL. Stat3: linking inflammation to (gastrointestinal) tumourigenesis. Clin Exp Pharmacol Physiol 2012; 39: 711-8.
90. [90] Pradere JP, Dapito DH, Schwabe RF. The Yin and Yang of Tolllike receptors in cancer. Oncogene 2014; 33: 3485-95.
91. [91] Terlizzi M, Casolaro V, Pinto A, Sorrentino R. Inflammasome: cancer's friend or foe? Pharmacol Ther 2014; 143: 24-33.
92. [92] Dutta J, Fan Y, Gupta N, Fan G, Gélinas C. Current insights into the regulation of programmed cell death by NF-kappaB. Oncogene 2006; 25: 6800-16.
93. [93] Fukata M, Chen A, Klepper A, et al. Cox-2 is regulated by Tolllike receptor-4 (TLR4) signaling: Role in proliferation and apoptosis in the intestine. Gastroenterology 2006; 131: 862-77.
94. [94] Hsu D, Fukata M, Hernandez YG, et al. Toll-like receptor 4 differentially regulates epidermal growth factor-related growth factors in response to intestinal mucosal injury. Lab Invest 2010; 90: 1295-305.
95. [95] Fukata M, Hernandez Y, Conduah D, et al. Innate immune signaling by Toll-like receptor-4 (TLR4) shapes the inflammatory microenvironment in colitis-associated tumors. Inflamm Bowel Dis 2009; 15: 997-1006.
96. [96] Fukata M, Shang L, Santaolalla R, et al. Constitutive activation of epithelial TLR4 augments inflammatory responses to mucosal injury and drives colitis-associated tumorigenesis. Inflamm Bowel Dis 2011; 17: 1464-73.
97. [97] Rakoff-Nahoum S, Medzhitov R. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science 2007; 317: 124-7.
98. [98] Cataisson C, Salcedo R, Hakim S, et al. IL-1R-MyD88 signaling in keratinocyte transformation and carcinogenesis. J Exp Med 2012; 209: 1689-702.
99. [99] Szajnik M, Szczepanski MJ, Czystowska M, et al. TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer. Oncogene 2009; 28: 4353-63.
100. [100] Szczepanski MJ, Czystowska M, Szajnik M, et al. Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res 2009; 69: 3105-13.
101. [101] He W, Liu Q, Wang L, et al. TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol Immunol 2007; 44: 2850-9.
102. [102] Lowe EL, Crother TR, Rabizadeh S, et al. Toll-like receptor 2 signaling protects mice from tumor development in a mouse model of colitis-induced cancer. PLoS One 2010; 5: e13027.
103. [103] Rhee SH, Im E, Pothoulakis C. Toll-like receptor 5 engagement modulates tumor development and growth in a mouse xenograft model of human colon cancer. Gastroenterology 2008; 135: 518-28.
104. [104] Salcedo R, Worschech A, Cardone M, et al. MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18. J Exp Med 2010; 207: 1625-36.
105. [105] Morikawa T, Sugiyama A, Kume H, et al. Identification of Tolllike receptor 3 as a potential therapeutic target in clear cell renal cell carcinoma. Clin Cancer Res 2007; 13: 5703-9.
106. [106] Salaun B, Lebecque S, Matikainen S, Rimoldi D, Romero P. Tolllike receptor 3 expressed by melanoma cells as a target for therapy? Clin Cancer Res 2007; 13: 4565-74.
107. [107] Salaun B, Coste I, Rissoan MC, Lebecque SJ, Renno T. TLR3 can directly trigger apoptosis in human cancer cells. J Immunol 2006; 176: 4894-901.
108. [108] Paone A, Starace D, Galli R, et al. Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC-alphadependent mechanism. Carcinogenesis 2008; 29: 1334-42.
109. [109] Germano G, Allavena P, Mantovani A. Cytokines as a key component of cancer-related inflammation. Cytokine 2008; 43: 374-9.
110. [110] Dinarello CA. Why not treat human cancer with interleukin-1 blockade? Cancer Metastasis Rev 2010; 29: 317-29.
111. [111] Dinarello CA. Overview of the interleukin-1 family of ligands and receptors. Semin Immunol 2013; 25: 389-93.
112. [112] Lewis AM, Varghese S, Xu H, Alexander HR. Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. J Transl Med 2006; 4: 48.
113. [113] Elaraj DM, Weinreich DM, Varghese S, et al. The role of interleukin 1 in growth and metastasis of human cancer xenografts. Clin Cancer Res 2006; 12: 1088-96.
114. [114] Zitvogel L, Kepp O, Galluzzi L, Kroemer G. Inflammasomes in carcinogenesis and anticancer immune responses. Nat Immunol 2012; 13: 343-51.
115. [115] Sade-Feldman M, Kanterman J, Ish-Shalom E, et al. Tumor necrosis factor-α blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation. Immunity 2013; 38: 541-54.
116. [116] Waters JP, Pober JS, Bradley JR. Tumour necrosis factor and cancer. J Pathol 2013; 230: 241-8.
117. [117] Grivennikov SI, Karin M. Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. Ann Rheum Dis 2011; 70: i104-i108.
118. [118] Li Y, Wang L, Pappan L, Galliher-Beckley A, Shi J. IL-1β promotes stemness and invasiveness of colon cancer cells through Zeb1 activation. Mol Cancer 2012; 11: 87.
119. [119] Tu S, Bhagat G, Cui G, et al. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloidderived suppressor cells in mice. Cancer Cell 2008; 14: 408-19.
120. [120] Voronov E, Shouval DS, Krelin Y, et al. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci USA 2003; 100: 2645-50.
121. [121] Krelin Y, Voronov E, Dotan S, et al. Interleukin-1beta-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors. Cancer Res 2007; 67: 1062-71.
122. [122] Lebeis SL, Powell KR, Merlin D, Sherman MA, Kalman D. Interleukin-1 receptor signaling protects mice from lethal intestinal damage caused by the attaching and effacing pathogen Citrobacter rodentium. Infect Immun 2009; 77: 604-14.
123. [123] Terme M, Ullrich E, Aymeric L, et al. IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Res 2011; 71: 5393-9.
124. [124] Zhernakova A, Festen EM, Franke L, et al. Genetic analysis of innate immunity in Crohn's disease and ulcerative colitis identifies two susceptibility loci harboring CARD9 and IL18RAP. Am J Hum Genet 2008; 82: 1202-10.
125. [125] Ghiringhelli F, Apetoh L, Tesniere A, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1betadependent adaptive immunity against tumors. Nat Med 2009; 15: 1170-8.
126. [126] Eisenbarth SC, Flavell RA. Innate instruction of adaptive immunity revisited: the inflammasome. EMBO Mol Med 2009; 1: 92-8.
127. [127] Salcedo R, Cataisson C, Hasan U, Yuspa SH, Trinchieri G. MyD88 and its divergent toll in carcinogenesis. Trends Immunol 2013; 34: 379-89.
128. [128] Inoue H, Tani K. Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments. Cell Death Differ 2014; 21: 39-49.
129. [129] Winter RN, Rhee JG, Kyprianou N. Caspase-1 enhances the apoptotic response of prostate cancer cells to ionizing radiation. Anticancer Res 2004; 24(3a): 1377-86.
130. [130] López-Castejón G, Pelegrín P. Current status of inflammasome blockers as anti-inflammatory drugs. Expert Opin Investig Drugs 2012; 21: 995-1007.
131. [131] Gasse P, Mary C, Guenon I, et al. IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice. J Clin Invest 2007; 117: 3786-99.
132. [132] Wu ZQ, Han XD, Wang Y, et al. Interleukin-1 receptor antagonist reduced apoptosis and attenuated intestinal mucositis in a 5-fluorouracil chemotherapy model in mice. Cancer Chemother Pharmacol 2011; 68: 87-96.
133. [133] Sauter KA, Wood LJ, Wong J, Iordanov M, Magun BE. Doxorubicin and daunorubicin induce processing and release of interleukin-1β through activation of the NLRP3 inflammasome. Cancer Biol Ther 2011; 11: 1008-16.
134. [134] Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 2012; 11: 633-52.
135. [135] MacKenzie SH, Schipper JL, Clark AC. The potential for caspases in drug discovery. Curr Opin Drug Discov Devel 2010; 13: 568-76.
136. [136] Keller M, Sollberger G, Beer HD. Thalidomide inhibits activation of caspase-1. J Immunol 2009; 183: 5593-9.
137. [137] Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 2011; 8: 151-60.
138. [138] Locher C, Conforti R, Aymeric L, et al. Desirable cell death during anticancer chemotherapy. Ann NY Acad Sci 2010; 1209: 99-108.
139. [139] Iyer SS, Pulskens WP, Sadler JJ, et al. Necrotic cells trigger a sterile inflammatory response through the Nlrp3 inflammasome. Proc Natl Acad Sci USA 2009; 106: 20388-93.
140. [140] Mattarollo SR, Loi S, Duret H, et al. Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res 2011; 71: 4809-20.
141. [141] Bruchard M, Mignot G, Derangère V, et al. Chemotherapytriggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med 2013; 19: 57-64.